share_log

Avenue Therapeutics | DEFA14A: Others

Avenue Therapeutics | DEFA14A: Others

Avenue Therapeutics | DEFA14A:其他
美股sec公告 ·  05/06 12:47
Moomoo AI 已提取核心訊息
Avenue Therapeutics, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Avenue Therapeutics itself, indicating that they are not preliminary proxy statements nor are they soliciting material under §240.14a-12. Furthermore, the company has confirmed that no filing fee is required for this submission.
Avenue Therapeutics, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Avenue Therapeutics itself, indicating that they are not preliminary proxy statements nor are they soliciting material under §240.14a-12. Furthermore, the company has confirmed that no filing fee is required for this submission.
作爲委託書的一部分,Avenue Therapeutics, Inc.已向美國證券交易委員會(SEC)提交了明確的額外材料。該文件根據附表14A提交,符合1934年《證券交易法》第14(a)條。這些材料是由Avenue Therapeutics自己提交的,表明它們不是初步的委託書,也不是根據第240.14a-12條徵集材料。此外,該公司已確認本次提交不需要任何申請費。
作爲委託書的一部分,Avenue Therapeutics, Inc.已向美國證券交易委員會(SEC)提交了明確的額外材料。該文件根據附表14A提交,符合1934年《證券交易法》第14(a)條。這些材料是由Avenue Therapeutics自己提交的,表明它們不是初步的委託書,也不是根據第240.14a-12條徵集材料。此外,該公司已確認本次提交不需要任何申請費。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息